XML 51 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Note 4 - Income Taxes - Component of Deferred Tax Assets (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Stock option expense $ 947,400 $ 689,600
NOL carryforward 10,509,900 7,080,600
Research and development credits 1,656,500 1,656,500
Unrealized gain from investment in Alphazyme (72,100) (69,800)
Other (6,100) 7,900
Deferred tax asset, net of deferred tax liabilities 13,035,600 9,364,800
Valuation allowance (13,035,600) (9,364,800)
Net deferred tax asset $ 0 $ 0